Osteopontin splice variants and polymorphisms in cancer progression and prognosis

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1868, Issue 1, 2017, Pages 93-108

  Briones Orta, Marco Antonio ^a   Avendaño Vázquez, S Eréndira ^b   Aparicio Bautista, Diana Ivette ^b   Coombes, Jason D ^a   Weber, Georg F ^c   Syn, Wing Kin ^a,d,e  

^a INSTITUTE OF HEPATOLOGY   (United Kingdom)

^b INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

^c UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Alternative splicing isoforms; Malignancy; Prognosis; Single nucleotide polymorphisms (SNPs); Spp1

Indexed keywords

ALTERNATIVE RNA SPLICING; CANCER GENETICS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CHROMOSOME; GENE; HAPLOTYPE; HUMAN; PHYLOGENY; PROMOTER REGION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SPP1 GENE; AMINO ACID SEQUENCE; DISEASE COURSE; GENETIC POLYMORPHISM; GENETICS; NEOPLASM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; RNA SPLICING;

OSTEOPONTIN;

AMINO ACID SEQUENCE; BASE SEQUENCE; DISEASE PROGRESSION; HUMANS; NEOPLASMS; OSTEOPONTIN; POLYMORPHISM, GENETIC; PROGNOSIS; RNA SPLICING;

EID: 85014768524     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2017.02.005     Document Type: Review

References (101)

1. [1] Wood, L.D., Parsons, D.W., Jones, S., Lin, J., Sjöblom, T., Leary, R.J., Shen, D., Boca, S.M., Barber, T., Ptak, J., Silliman, N., Szabo, S., Dezso, Z., Ustyanksky, V., Nikolskaya, T., Nikolsky, Y., Karchin, R., Wilson, P.A., Kaminker, J.S., Zhang, Z., et al. The genomic landscapes of human breast and colorectal cancers. Science 318 (2007), 1108–1113.
2. [2] Sottoriva, A., Kang, H., Ma, Z., Graham, T.A., Salomon, M.P., Zhao, J., Marjoram, P., Siegmund, K., Press, M.F., Shibata, D., Curtis, C., A Big Bang model of human colorectal tumor growth. Nat. Genet. 47 (2015), 209–216.
3. [3] Anborgh, P.H., Mutrie, J.C., Tuck, A.B., Chambers, A.F., Pre- and post-translational regulation of osteopontin in cancer. J. Cell Commun. Signal. 5 (2011), 111–122.
4. [4] Anwar, A., Li, M., Frid, M.G., Kumar, B., Gerasimovskaya, E.V., Riddle, S.R., McKeon, B.A., Thukaram, R., Meyrick, B.O., Fini, M.A., Stenmark, K.R., Osteopontin is an endogenous modulator of the constitutively activated phenotype of pulmonary adventitial fibroblasts in hypoxic pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 303 (2012), L1–L11.
5. [5] Fedarko, N.S., Jain, A., Karadag, A., Van Eman, M.R., Fisher, L.W., Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin. Cancer Res. 7 (2001), 4060–4066.
6. [6] Gimba, E.R., Tilli, T.M., Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Lett. 331 (2013), 11–17.
7. [7] He, B., Mirza, M., Weber, G.F., An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 25 (2006), 2192–2202.
8. [8] Tilli, T.M., Franco, V.F., Robbs, B.K., Wanderley, J.L.M., Da Silva, F.R. De A., de Mello, K.D., Viola, J.P.B., Weber, G.F., Gimba, E.R., Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol. Cancer Res. 9 (2011), 280–293.
9. [9] Tilli, T.M., Thuler, L.C., Matos, A.R., Coutinho-Camillo, C.M., Soares, F.A., da Silva, E.A., Neves, A.F., Goulart, L.R., Gimba, E.R., Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp. Mol. Pathol. 92 (2012), 13–19.
10. [10] Weber, G.F., The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim. Biophys. Acta 1552 (2001), 61–85.
11. [11] Sodek, J., Ganss, B., McKee, M.D., Osteopontin. Crit. Rev. Oral Biol. Med. 11 (2000), 279–303.
12. [12] Bandopadhyay, M., Bulbule, A., Butti, R., Chakraborty, G., Ghorpade, P., Ghosh, P., Gorain, M., Kale, S., Kumar, D., Kumar, S., Totakura, K.V.S., Roy, G., Sharma, P., Shetti, D., Soundararajan, G., Thorat, D., Tomar, D., Nalukurthi, R., Raja, R., Mishra, R., et al. Osteopontin as a therapeutic target for cancer. Expert Opin. Ther. Targets 18 (2014), 883–895.
13. [13] Weber, G.F., Lett, G.S., Haubein, N.C., Osteopontin is a marker for cancer aggressiveness and patient survival. Br. J. Cancer 103 (2010), 861–869.
14. [14] Fisher, L.W., Torchia, D.A., Fohr, B., Young, M.F., Fedarko, N.S., Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem. Biophys. Res. Commun. 280 (2001), 460–465.
15. [15] Huq, N.L., Cross, K.J., Ung, M., Reynolds, E.C., A review of protein structure and gene organisation for proteins associated with mineralised tissue and calcium phosphate stabilisation encoded on human chromosome 4. Arch. Oral Biol. 50 (2005), 599–609.
16. [16] Sire, J.-Y., Davit-Béal, T., Delgado, S., Gu, X., The origin and evolution of enamel mineralization genes. Cells Tissues Organs (Print) 186 (2007), 25–48.
17. [17] Yoshizaki, K., Yamada, Y., Gene evolution and functions of extracellular matrix proteins in teeth. Orthod Waves 72 (2013), 1–10.
18. [18] Bellahcène, A., Castronovo, V., Ogbureke, K.U.E., Fisher, L.W., Fedarko, N.S., Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat. Rev. Cancer 8 (2008), 212–226.
19. [19] Delgado, S., Girondot, M., Sire, J.-Y., Molecular evolution of amelogenin in mammals. J. Mol. Evol. 60 (2005), 12–30.
20. [20] Fisher, L.W., Fedarko, N.S., Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect. Tissue Res. 44:Suppl. 1 (2003), 33–40.
21. [21] Hijiya, N., Setoguchi, M., Matsuura, K., Higuchi, Y., Akizuki, S., Yamamoto, S., Cloning and characterization of the human osteopontin gene and its promoter. Biochem. J. 303 (1994), 255–262.
22. [22] Rowe, P.S.N., The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled. Cell Biochem. Funct. 30 (2012), 355–375.
23. [23] Saitoh, Y., Kuratsu, J., Takeshima, H., Yamamoto, S., Ushio, Y., Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab. Investig. 72 (1995), 55–63.
24. [24] Young, M.F., Kerr, J.M., Termine, J.D., Wewer, U.M., Wang, M.G., McBride, O.W., Fisher, L.W., cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 7 (1990), 491–502.
25. [25] Farrell, C.M., O'Leary, N.A., Harte, R.A., Loveland, J.E., Wilming, L.G., Wallin, C., Diekhans, M., Barrell, D., Searle, S.M.J., Aken, B., Hiatt, S.M., Frankish, A., Suner, M.-M., Rajput, B., Steward, C.A., Brown, G.R., Bennett, R., Murphy, M., Wu, W., Kay, M.P., et al. Current status and new features of the Consensus Coding Sequence database. Nucleic Acids Res. 42 (2014), D865–D872.
26. [26] Harte, R.A., Farrell, C.M., Loveland, J.E., Suner, M.-M., Wilming, L., Aken, B., Barrell, D., Frankish, A., Wallin, C., Searle, S., Diekhans, M., Harrow, J., Pruitt, K.D., Tracking and coordinating an international curation effort for the CCDS Project. Database (Oxford), 2012, 2012, bas008.
27. [27] Pruitt, K.D., Harrow, J., Harte, R.A., Wallin, C., Diekhans, M., Maglott, D.R., Searle, S., Farrell, C.M., Loveland, J.E., Ruef, B.J., Hart, E., Suner, M.-M., Landrum, M.J., Aken, B., Ayling, S., Baertsch, R., Fernandez-Banet, J., Cherry, J.L., Curwen, V., Dicuccio, M., et al. The consensus coding sequence (CCDS) project: identifying a common protein-coding gene set for the human and mouse genomes. Genome Res. 19 (2009), 1316–1323.
28. [28] Yates, A., Akanni, W., Amode, M.R., Barrell, D., Billis, K., Carvalho-Silva, D., Cummins, C., Clapham, P., Fitzgerald, S., Gil, L., Girón, C.G., Gordon, L., Hourlier, T., Hunt, S.E., Janacek, S.H., Johnson, N., Juettemann, T., Keenan, S., Lavidas, I., Martin, F.J., et al. Ensembl 2016. Nucl. Acids Res. 44 (2016), D710–D716.
29. [29] Christensen, B., Nielsen, M.S., Haselmann, K.F., Petersen, T.E., Sørensen, E.S., Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem. J. 390 (2005), 285–292.
30. [30] Sørensen, E.S., Rasmussen, L.K., Møller, L., Jensen, P.H., Højrup, P., Petersen, T.E., Localization of transglutaminase-reactive glutamine residues in bovine osteopontin. Biochem. J. 304:Pt 1 (1994), 13–16.
31. [31] Wang, M., Marín, A., Characterization and prediction of alternative splice sites. Gene 366 (2006), 219–227.
32. [32] Reese, M.G., Eeckman, F.H., Kulp, D., Haussler, D., Improved splice site detection in Genie. J. Comput. Biol. 4 (1997), 311–323.
33. [33] Higashikawa, F., Eboshida, A., Yokosaki, Y., Enhanced biological activity of polymeric osteopontin. FEBS Lett. 581 (2007), 2697–2701.
34. [34] Ortiz-Martínez, F., Perez-Balaguer, A., Ciprián, D., Andrés, L., Ponce, J., Adrover, E., Sánchez-Payá, J., Aranda, F.I., Lerma, E., Peiró, G., Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence. Hum. Pathol. 45 (2014), 504–512.
35. [35] Mirza, M., Shaughnessy, E., Hurley, J.K., Vanpatten, K.A., Pestano, G.A., He, B., Weber, G.F., Osteopontin-c is a selective marker of breast cancer. Int. J. Cancer 122 (2008), 889–897.
36. [36] Pang, H., Lu, H., Song, H., Meng, Q., Zhao, Y., Liu, N., Lan, F., Liu, Y., Yan, S., Dong, X., Cai, L., Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer. Cancer Epidemiol. 37 (2013), 985–992.
37. [37] Patani, N., Jiang, W., Mokbel, K., Osteopontin C mRNA expression is associated with a poor clinical outcome in human breast cancer. Int. J. Cancer, 122, 2008, 2646.
38. [38] Weber, G.F., The cancer biomarker osteopontin: combination with other markers. Cancer Genomics Proteomics 8 (2011), 263–288.
39. [39] Weber, G.F., Lett, G.S., Haubein, N.C., Categorical meta-analysis of osteopontin as a clinical cancer marker. Oncol. Rep. 25 (2011), 433–441.
40. [40] Patani, N., Jouhra, F., Jiang, W., Mokbel, K., Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res. 28 (2008), 4105–4110.
41. [41] Zduniak, K., Ziolkowski, P., Ahlin, C., Agrawal, A., Agrawal, S., Blomqvist, C., Fjällskog, M.-L., Weber, G.F., Nuclear osteopontin-c is a prognostic breast cancer marker. Br. J. Cancer 112 (2015), 729–738.
42. [42] Hartung, F., Weber, G.F., RNA blood levels of osteopontin splice variants are cancer markers. Springerplus, 2, 2013, 110.
43. [43] Zduniak, K., Agrawal, A., Agrawal, S., Hossain, M.M., Ziolkowski, P., Weber, G.F., Osteopontin splice variants are differential predictors of breast cancer treatment responses. BMC Cancer, 16, 2016, 441.
44. [44] Wu, J., Pungaliya, P., Kraynov, E., Bates, B., Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry. Biomarkers 17 (2012), 125–133.
45. [45] Goparaju, C.M.V., Pass, H.I., Blasberg, J.D., Hirsch, N., Donington, J.S., Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J. Thorac. Oncol. 5 (2010), 1516–1523.
46. [46] Zhao, B., Sun, T., Meng, F., Qu, A., Li, C., Shen, H., Jin, Y., Li, W., Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer. J. Cancer Res. Clin. Oncol. 137 (2011), 1061–1070.
47. [47] Ivanov, S.V., Ivanova, A.V., Goparaju, C.M.V., Chen, Y., Beck, A., Pass, H.I., Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochem. Biophys. Res. Commun. 382 (2009), 514–518.
48. [48] Chae, S., Jun, H.-O., Lee, E.G., Yang, S.-J., Lee, D.C., Jung, J.K., Park, K.C., Yeom, Y.I., Kim, K.-W., Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int. J. Oncol. 35 (2009), 1409–1416.
49. [49] Phillips, R.J., Helbig, K.J., Van der Hoek, K.H., Seth, D., Beard, M.R., Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner. World J. Gastroenterol. 18 (2012), 3389–3399.
50. [50] Takafuji, V., Forgues, M., Unsworth, E., Goldsmith, P., Wang, X.W., An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 26 (2007), 6361–6371.
51. [51] Sarosiek, K., Jones, E., Chipitsyna, G., Al-Zoubi, M., Kang, C., Saxena, S., Gandhi, A.V., Sendiky, J., Yeo, C.J., Arafat, H.A., Osteopontin (OPN) isoforms, diabetes, obesity, and cancer; what is one got to do with the other? A new role for OPN. J. Gastrointest. Surg. 19 (2015), 639–650.
52. [52] Sullivan, J., Blair, L., Alnajar, A., Aziz, T., Ng, C.Y., Chipitsyna, G., Gong, Q., Witkiewicz, A., Weber, G.F., Denhardt, D.T., Yeo, C.J., Arafat, H.A., Expression of a prometastatic splice variant of osteopontin, OPNC. Human pancreatic ductal adenocarcinoma Surgery, 146, 2009, 232–240.
53. [53] Sullivan, J., Blair, L., Alnajar, A., Aziz, T., Chipitsyna, G., Gong, Q., Yeo, C.J., Arafat, H.A., Expression and regulation of nicotine receptor and osteopontin isoforms in human pancreatic ductal adenocarcinoma. Histol. Histopathol. 26 (2011), 893–904.
54. [54] Siddiqui, A.A., Jones, E., Andrade, D., Shah, A., Kowalski, T.E., Loren, D.E., Chipitsyna, G., Arafat, H.A., Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinoma. J. Gastroenterol. Hepatol. 29 (2014), 1321–1327.
55. [55] Lin, J., Myers, A.L., Wang, Z., Nancarrow, D.J., Ferrer-Torres, D., Handlogten, A., Leverenz, K., Bao, J., Thomas, D.G., Wang, T.D., Orringer, M.B., Reddy, R.M., Chang, A.C., Beer, D.G., Lin, L., Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma. Oncotarget 6 (2015), 22239–22257.
56. [56] Zhang, M.-X., Xu, Y.-J., Zhu, M.-C., Yan, F., Overexpressed ostepontin-c as a potential biomarker for esophageal squamous cell carcinoma. Asian Pac. J. Cancer Prev. 14 (2013), 7315–7319.
57. [57] Tang, X., Li, J., Yu, B., Su, L., Yu, Y., Yan, M., Liu, B., Zhu, Z., Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer. Int. J. Biol. Sci. 9 (2013), 55–66.
58. [58] Sreekanthreddy, P., Srinivasan, H., Kumar, D.M., Nijaguna, M.B., Sridevi, S., Vrinda, M., Arivazhagan, A., Balasubramaniam, A., Hegde, A.S., Chandramouli, B.A., Santosh, V., Rao, M.R.S., Kondaiah, P., Somasundaram, K., Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol. Biomark. Prev. 19 (2010), 1409–1422.
59. [59] Yan, W., Qian, C., Zhao, P., Zhang, J., Shi, L., Qian, J., Liu, N., Fu, Z., Kang, C., Pu, P., You, Y., Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro-Oncology 12 (2010), 765–775.
60. [60] Güttler, A., Giebler, M., Cuno, P., Wichmann, H., Keßler, J., Ostheimer, C., Söling, A., Strauss, C., Illert, J., Kappler, M., Vordermark, D., Bache, M., Osteopontin and splice variant expression level in human malignant glioma: radiobiologic effects and prognosis after radiotherapy. Radiother. Oncol. 108 (2013), 535–540.
61. [61] Courter, D., Cao, H., Kwok, S., Kong, C., Banh, A., Kuo, P., Bouley, D.M., Vice, C., Brustugun, O.T., Denko, N.C., Koong, A.C., Giaccia, A., Le, Q.-T., The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS One, 5, 2010, e9633.
62. [62] Ferreira, L.B., Eloy, C., Pestana, A., Lyra, J., Moura, M., Prazeres, H., Tavares, C., Sobrinho-Simões, M., Gimba, E., Soares, P., Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma. Eur. J. Endocrinol. 174 (2016), 551–561.
63. [63] Hahnel, A., Wichmann, H., Greither, T., Kappler, M., Würl, P., Kotzsch, M., Taubert, H., Vordermark, D., Bache, M., Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients. BMC Cancer, 12, 2012, 131.
64. [64] Boguslawska, J., Sokol, E., Rybicka, B., Czubaty, A., Rodzik, K., Piekielko-Witkowska, A., microRNAs target SRSF7 splicing factor to modulate the expression of osteopontin splice variants in renal cancer cells. Gene 595 (2016), 142–149.
65. [65] Sherry, S.T., Ward, M.H., Kholodov, M., Baker, J., Phan, L., Smigielski, E.M., Sirotkin, K., dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29 (2001), 308–311.
66. [66] Zhang, R., Yang, W., Li, Y.C., Zhang, G.J., Yao, K., Hu, R., Wu, B., The OPN gene polymorphism confers the susceptibility and response to Ara-C based chemotherapy in Chinese AML patients. Cell. Physiol. Biochem. 35 (2015), 175–183.
67. [67] Shen, Z., Chen, B., Hou, X., Chen, P., Zhao, G., Fan, J., Polymorphism − 433 C > T of the osteopontin gene is associated with the susceptibility to develop gliomas and their prognosis in a Chinese cohort. Cell. Physiol. Biochem. 34 (2014), 1190–1198.
68. [68] Mu, G., Wang, H., Cai, Z., Ji, H., OPN − 443C > T genetic polymorphism and tumor OPN expression are associated with the risk and clinical features of papillary thyroid cancer in a Chinese cohort. Cell. Physiol. Biochem. 32 (2013), 171–179.
69. [69] Chang, Y.S., Kim, H.J., Chang, J., Ahn, C.M., Kim, S.K., Kim, S.K., Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 57 (2007), 373–380.
70. [70] Hao, Y., Liu, J., Wang, P., Wang, F., Yu, Z., Li, M., Chen, S., Ning, F., OPN polymorphism is related to the chemotherapy response and prognosis in advanced NSCLC. Int. J. Genomics, 2014, 2014, 846142.
71. [71] Zhao, X.-Q., Ma, H.-X., Su, M.-S., He, L., Osteopontin promoter polymorphisms at locus − 443 are associated with metastasis and poor prognosis of human intrahepatic cholangiocarcinoma in Chinese population. Int. J. Clin. Exp. Pathol. 7 (2014), 6914–6921.
72. [72] Schultz, J., Lorenz, P., Ibrahim, S.M., Kundt, G., Gross, G., Kunz, M., The functional − 443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor. Mol. Carcinog. 48 (2009), 14–23.
73. [73] Zhao, F., Chen, X., Meng, T., Hao, B., Zhang, Z., Zhang, G., Genetic polymorphisms in the osteopontin promoter increases the risk of distance metastasis and death in Chinese patients with gastric cancer. BMC Cancer, 12, 2012, 477.
74. [74] Chen, Y., Liu, H., Wu, W., Li, Y., Li, J., Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis. J. Exp. Clin. Cancer Res., 32, 2013, 45.
75. [75] Ramchandani, D., Weber, G.F., An osteopontin promoter polymorphism is associated with aggressiveness in breast cancer. Oncol. Rep. 30 (2013), 1860–1868.
76. [76] Dong, Q.-Z., Zhang, X.-F., Zhao, Y., Jia, H.-L., Zhou, H.-J., Dai, C., Sun, H.-J., Qin, Y., Zhang, W.-D., Ren, N., Ye, Q.-H., Qin, L.-X., Osteopontin promoter polymorphisms at locus − 443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma. Hepatology 57 (2013), 1024–1034.
77. [77] Wang, J., Nong, L., Wei, Y., Qin, S., Zhou, Y., Tang, Y., Association of osteopontin polymorphisms with nasopharyngeal carcinoma risk. Hum. Immunol. 75 (2014), 76–80.
78. [78] Liu, Y., Lei, H., Zhang, J., Wang, J., Li, K., Dong, W., Associations between the genetic polymorphisms of osteopontin promoter and susceptibility to cancer in Chinese population: a meta-analysis. PLoS One, 10, 2015, e0135318.
79. [79] Yang, G., Peng, X., Guo, P., Yang, G., Association of osteopontin polymorphism with cancer risk: a meta-analysis. Int. J. Clin. Exp. Med. 8 (2015), 20911–20917.
80. [80] Farré, D., Roset, R., Huerta, M., Adsuara, J.E., Roselló, L., Albà, M.M., Messeguer, X., Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res. 31 (2003), 3651–3653.
81. [81] Messeguer, X., Escudero, R., Farré, D., Núñez, O., Martínez, J., Albà, M.M., PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 18 (2002), 333–334.
82. [82] M.A. Briones-Orta, S. Avendano-Vazquez, D. Aparicio-Bautista, J.D. Coombes, G.F. Weber, W.K. Syn, Prediction of Transcription Factor Binding Sites affected by SNPs located at the Osteopontin Promoter, Data in Brief, (Submitted for publication).
83. [83] Bruns, H.A., Kaplan, M.H., The role of constitutively active Stat6 in leukemia and lymphoma. Crit. Rev. Oncol. Hematol. 57 (2006), 245–253.
84. [84] Gooch, J.L., Christy, B., Yee, D., STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells. Neoplasia 4 (2002), 324–331.
85. [85] Calò, V., Migliavacca, M., Bazan, V., Macaluso, M., Buscemi, M., Gebbia, N., Russo, A., STAT proteins: from normal control of cellular events to tumorigenesis. J. Cell. Physiol. 197 (2003), 157–168.
86. [86] Xu, Q., Yuan, B., Xue, F., Zhang, L., Li, J., Guo, H., Yue, T., OPN gene polymorphisms are associated with susceptibility and clinicopatholigical characteristics of cervical cancer in a Chinese cohort. Cancer Biomark. 10 (2011), 233–239.
87. [87] Chen, J., Wu, Q., Lu, Y., Xu, T., Huang, Y., Ribas, J., Ni, X., Hu, G., Huang, F., Zhou, L., Lu, D., SPP1 promoter polymorphisms and glioma risk in a Chinese Han population. J. Hum. Genet. 55 (2010), 456–461.
88. [88] Chiu, Y.-W., Tu, H.-F., Wang, I.-K., Wu, C.-H., Chang, K.-W., Liu, T.-Y., Kao, S.-Y., The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis. Oral Oncol. 46 (2010), 302–306.
89. [89] Lee, T.-Y., Lin, J.-T., Wu, C.-C., Yu, C.-C., Wu, M.-S., Lee, T.-C., Chen, H.-P., Wu, C.-Y., Osteopontin promoter polymorphisms are associated with susceptibility to gastric cancer. J. Clin. Gastroenterol. 47 (2013), e55–e59.
90. [90] Giacopelli, F., Marciano, R., Pistorio, A., Catarsi, P., Canini, S., Karsenty, G., Ravazzolo, R., Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol. Genomics 20 (2004), 87–96.
91. [91] Inman, C.K., Shore, P., The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J. Biol. Chem. 278 (2003), 48684–48689.
92. [92] Feng, C., Zhang, Y., Yin, J., Li, J., Abounader, R., Zuo, Z., Regulatory factor X1 is a new tumor suppressive transcription factor that acts via direct downregulation of CD44 in glioblastoma. Neuro-Oncology 16 (2014), 1078–1085.
93. [93] Engelmann, D., Pützer, B.M., The dark side of E2F1: in transit beyond apoptosis. Cancer Res. 72 (2012), 571–575.
94. [94] Bouafia, A., Corre, S., Gilot, D., Mouchet, N., Prince, S., Galibert, M.-D., p53 requires the stress sensor USF1 to direct appropriate cell fate decision. PLoS Genet., 10, 2014, e1004309.
95. [95] Lee, H.J., Hwang, M., Chattopadhyay, S., Choi, H.-S., Lee, K., Hepatocyte nuclear factor-3 alpha (HNF-3alpha) negatively regulates androgen receptor transactivation in prostate cancer cells. Biochem. Biophys. Res. Commun. 367 (2008), 481–486.
96. [96] Zhang, Y.-Q., Peng, L.-J., Cao, Y.-R., Zeng, Z.-P., Wu, Y.-J., Shi, H., Cheng, S.-Y., Wang, J.-Y., Friedman, S.L., Sninsky, J.J., Guo, J.-S., Risk factors for hepatocellular carcinoma in cirrhotic patients with chronic hepatitis B. Genet. Test. Mol. Biomarkers 20 (2016), 535–543.
97. [97] Hummelshoj, T., Ryder, L.P., Madsen, H.O., Odum, N., Svejgaard, A., A functional polymorphism in the Eta-1 promoter is associated with allele specific binding to the transcription factor Sp1 and elevated gene expression. Mol. Immunol. 43 (2006), 980–986.
98. [98] Wang, D., Yamamoto, S., Hijiya, N., Benveniste, E.N., Gladson, C.L., Transcriptional regulation of the human osteopontin promoter: functional analysis and DNA-protein interactions. Oncogene 19:50 (2000 Nov 23), 5801–5809.
99. [99] Barp, A., Bello, L., Politano, L., Melacini, P., Calore, C., Polo, A., Vianello, S., Sorarù, G., Semplicini, C., Pantic, B., Taglia, A., Picillo, E., Magri, F., Gorni, K., Messina, S., Vita, G.L., Vita, G., Comi, G.P., Ermani, M., Calvo, V., et al. Genetic modifiers of Duchenne muscular dystrophy and dilated cardiomyopathy. PLoS One, 10, 2015, e0141240.
100. [100] Fan, Y., Zhang, X., Yang, Z.-H., Sun, X.-W., Li, S.-N., Zhong, L., Cheng, X., Wang, Y., Ma, Y.-R., The polymorphisms of osteopontin gene and plasma osteopontin protein levels with susceptibility to colorectal carcinoma. DNA Cell Biol. 32 (2013), 594–600.
101. [101] Qiu, Y., Hu, Y., Zhang, Z.-Y., Ye, L., Xu, F.-H., Schneider, M.E., Ma, X.-L., Du, Y.-X., Zuo, X.-B., Zhou, F.-S., Chen, G., Xie, X.-S., Zhang, Y., Xia, H.-Z., Wu, J.-F., Du, W.-D., Genetic association of osteopontin (OPN) and its receptor CD44 genes with susceptibility to Chinese gastric cancer patients. J. Cancer Res. Clin. Oncol. 140 (2014), 2143–2156.